

AUTOMATE YOUR GENOME ENGINEERING

CRISPR Done for You

Engineered Cells products deliver your desired edit in your preferred cell type with guaranteed results. We've optimized CRISPR. You focus on the discoveries.

[Synthego.com/CSHL](https://synthego.com/CSHL)

CRISPR Applications for Engineered Cells



Gene & Protein
Function



Protein Tagging and
Engineering



Assay & Antibody
Validation



Pathway
Analysis



Disease
Models



Precision
Editing

Did you get the message?

In recent years, the discovery of new classes and modifications of RNA has ushered in a renaissance of RNA-focused research. Did you know that NEB[®] offers a broad portfolio of reagents for the purification, quantitation, detection, synthesis and manipulation of RNA? Experience improved performance and increased yields, enabled by our expertise in enzymology.



FEATURED PRODUCTS *for* RNA RESEARCH:

NEW Monarch[®] RNA Purification Kits –

kits available for isolation of total RNA from various sample types and for RNA cleanup following extraction, synthesis and other enzymatic reactions

NEW Luna[®] RT-qPCR products –

optimized solutions for one-step or two-step RT-qPCR, featuring the novel Luna Reverse Transcriptase

NEW NEBNext[®] Ultra[™] II RNA Library Prep Kits –

generate high quality RNA-seq libraries, even with limited amounts of RNA

HiScribe[™] *in vitro* Transcription Kits –

rapidly synthesize high yields of high quality RNA

Let NEB help streamline your **RNA-related workflows**.
Get started at **NEB[®]rna.com**



THE LEADERS IN RNA.

Take a new approach to better predict therapy response with multidimensional biomarkers.



ImmunoPrism™ Research Only Service

Leverage Cofactor's Health Expression Models to enable robust solid tumor immune characterization, immune escape gene characterization, and multidimensional biomarker discovery.



ImmunoPrism™ CAP Accredited Service

Submit patient materials directly to our scientific experts and gain access to our CAP/CLIA laboratory with this clinically-validated assay.



ImmunoPrism™ Reagent Kit & Informatics

Use your own sequencing resources and apply the same reagents and machine-learning algorithms validated in our laboratories to derive powerful multidimensional immune biomarkers.

Mention this ad for 10% off your first project.*

sales@cofactorgenomics.com | 888.602.0448 | 300 Brannan St, San Francisco, CA 94107


Cofactor's ImmunoPrism™ Assay is offered both for Research Use Only (not to be used as a diagnostic assay) and as a CAP-validated assay. Please contact us to discuss which option is right for your application.

*New customers only. Minimum sample number and quality may apply.



One choice, many possibilities

Collect samples in **PAXgene® Blood RNA Tubes** and choose from a variety of validated options to purify intracellular RNA



- ❖ **Stabilize intracellular RNA** in blood at the point of collection and purify now or in the future
- ❖ Choose the optimal purification method **tailored to your specific needs**
- ❖ **Streamline processing** with efficient manual or automated protocols
- ❖ Purify miRNA with an optimized protocol for **total RNA including miRNA** using the **PAXgene Blood miRNA Kit***




* The PAXgene Blood miRNA Kit (763134), the PAXgene 96 Blood RNA Kit (762331) and the QIAAsymphony PAXgene Blood RNA Kit (762635) are for Research Use Only. Not for use in diagnostic procedures.

The PAXgene Blood RNA System is for IVD use and consists of the PAXgene Blood RNA Tube (762165) and the PAXgene Blood RNA Kit (762164 or 762174).

Explore more at **www.preanalytix.com**


PROM-10588-003 © 2019 PreAnalytiX GmbH. PreAnalytiX, the PreAnalytiX logo and PAXgene are trademarks of PreAnalytiX GmbH, Hombrechtikon, CH.

 **PreAnalytiX**
A QIAGEN / BD Company



2019–2020 SCIENTIFIC CONFERENCES

Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment



Pancreatic Cancer: Advances in Science and Clinical Care

Conference Cochair: Dafna Bar-Sagi,
Luis A. Diaz, Elizabeth M. Jaffee,
Ben Z. Stanger, and Brian M. Wolpin
September 6-9, 2019 | Boston, MA



Advances in Ovarian Cancer Research

Conference Cochair: Carol Aghajanian,
David D. L. Bowtell, George Coukos,
Alan D. D'Andrea, and Karen H. Lu
September 13-16, 2019 | Atlanta, GA

Advances in Pediatric Cancer Research

Conference Cochair: Crystal Mackall, David Malkin,
Stefan Pfister, and Kimberly Stegmaier
September 17-20, 2019 | Montreal, QC, Canada




12th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Conference Chair: Laura Fejerman
September 20-23, 2019 | San Francisco, CA

Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Conference Cochair: Christoph Huber,
Guido Kroemer, Ellen Puré, and Giorgio Trinchieri
September 25-28, 2019 | Paris, France



Cancer Research UK-AACR Joint Conference: Engineering and Physical Sciences in Oncology

Conference Cochair: Sangeeta N. Bhatia,
Kevin M. Brindle, Joe W. Gray, and Molly Stevens
October 15-17, 2019 | London, England

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Organizing Committee Cochair: Elizabeth M. Jaffee,
James H. Doroshow, and Denis A. Lacombe
October 26-30, 2019 | Boston, MA

AACR International Conference: Infection and Cancer

Conference Chair: Tak W. Mak
November 8-10, 2019 | Hong Kong

Tumor Immunology and Immunotherapy

Conference Cochair: Timothy A. Chan,
Charles G. Drake, Marcela V. Maus,
and Arlene H. Sharpe
November 17-20, 2019 | Boston, MA

San Antonio Breast Cancer Symposium

Codirectors: Carlos L. Arteaga,
Virginia G. Kaklamani, and C. Kent Osborne
December 10-14, 2019 | San Antonio, TX

Advancing Precision Medicine Drug Development: Incorporation of Real World Data and Other Novel Strategies


Conference Cochair: David M. Hyman,
Elaine R. Mardis, Lillian L. Siu, and Eliezer M. Van Allen
January 9-12, 2020 | San Diego, CA

Sixth AACR-IASLC International Joint Conference: Lung Cancer

January 11-14, 2020 | San Diego, CA

Advances in Liquid Biopsies

Conference Cochair: Luis A. Diaz Jr.,
Maximilian Diehn, Irene M. Ghobrial,
and Nicholas C. Turner
January 13-16, 2020 | Miami, FL



Learn more and register at
AACR.org/Calendar

AACR American Association
for Cancer Research®
FINDING CURES TOGETHER®

THE QUALITY OF YOUR PCR PLASTICS MATTERS



High-quality plastics give you confidence in your qPCR results

Completely eliminate plates and seals as a potential source of error in your qPCR workflow. Bio-Rad's premium PCR plastics and seals undergo rigorous QC to ensure the highest quality products are delivered. From our rigid Hard-Shell Plates that maintain plate shape during thermal cycling to our Microseal 'B' Seals that prevent evaporation, you can be confident these products will help you obtain accurate and reproducible results, every time.

Learn more at [bio-rad.com/PCRplastics](https://www.bio-rad.com/PCRplastics)

Bio-Rad, Hard-Shell, and Microseal are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

BIO-RAD


A REVOLUTION in Co-Transcriptional mRNA Capping

CleanCap® demonstrates superior performance versus legacy co-transcriptional capping methods


	Legacy Cap Analogs		CleanCap®	
Natural Cap	No	-	Yes	+
Immunogenic	Yes	-	Reduced Immunogenicity	+
Capping Efficiency	~70%	-	~95%	+
Yield/mL Transcription	1.5 mg/mL	-	4 mg/mL	+
Cost	3 X	-	1 X	+
Available Therapeutic Licenses	No	-	Yes	+

CleanCap®

Successful development of mRNA therapeutics relies on reproducible, high-efficiency production of capped mRNA. CleanCap® uses a new co-transcriptional chemical process for the highest level of mRNA capping:



CleanCap® gives superior activity *in vivo* by mimicking a natural cap



Luciferase mRNA was formulated with Lunar Lipids and injected by tail vein into mice. At 6 hours, luciferase was measured by western blot in mouse liver. Data courtesy of Arcturus Therapeutics.

CleanCap® results in a natural Cap 1 structure that does not stimulate the innate immune system of the host, resulting in unparalleled efficiency *in vivo*. Legacy co-transcriptional capping methods yield a Cap 0, an immunogenic cap structure that is poorly expressed *in vivo*.

The results speak for themselves: **CleanCap®, the next generation of cap analogs, provide the most active and least toxic mRNA for your *in vivo* applications.**

Be part of the revolution.

For more information visit: trilinkbiotech.com/cleancap